Robert Clark Brown, MD, PhD, Children’s Healthcare of Atlanta, Atlanta, GA, talks on the FDA approval of voxelotor for patients with sickle cell disease (SCD) based on the ability to increase patients’ hemoglobin 1g above baseline, and discusses studies investigating other clinical outcomes associated with voxelotor therapy. Dr Brown highlights data from the HOPE Kids 2 trial (NCT04218084), which is evaluating the efficacy of voxelotor in pediatric patients aged 2-15 with SCD, and is collecting transcranial Doppler ultrasound (TCD) measurements in participants to assess the risk of stroke. Dr Brown also talks on data from the ActIVe study (NCT04400487) which is measuring actigraphy improvement with voxelotor in patients with SCD or sickle cell anemia. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.